Japanese cedar pollinosis
Conditions
Interventions
1)Japanese cedar pollen allergy relief rice 80g intake group (allergy rerief rice 80g once a day, for 8 weeks, 7cases)
2)the placebo group (pracebo rice 80g once a day, for 8 weeks, 3 cases)
Sponsors
Osaka Habikino Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)those who have no symptoms related allergic rhinitis consistent with the cedar pollen season 2)those whose Japanese cedar pollen allergen-specific IgE antibody titer show class the 2 or 3 (measured by AlaSTAT 3g method) 3)those whose Japanese ceder pollen-specific T cell proliferative response show positive 4)those who live or work in Osaka prefecture and consented to research participation by the document from the person obtained 5)those who can comply with not to transfer the test product to a third party
Exclusion criteria
Exclusion criteria: 1)those whom Principal Investigator or the sharing researchers have determined inappropriate 2)those who suffer from rice allergy or have a history of rice allergy 3)those who have received immunotherapy for cedar pollen, or have the schedule 4)those who suffer from some serious disease with disease activity, therefore, are judged unsuitable for enrolement by the clinician 5)those who are or planning to become pregnant or in the process of breast-feeding during the clinical reseach 6)those who are participating in other clinical research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Japanese cedar pollen-specific T cell proliferative response at 0, 4, 8 weeks after the start of ingestion | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)serum Japanese cedar pollen-specific IgE antibody level at 0, 4, 8 weeks after the start of ingestion 2)adverse events from the start to the end of ingestion | — |
Countries
Japan
Contacts
Public ContactShoji Hashimoto
Osaka Habikino Medical Center Department of Clinical Research & Development
Outcome results
None listed